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Objective: This white paper constitutes an overview of presentations and discussions from the ﬁfth
Annual Workshop on Imaging in Osteoarthritis (OA) held in Salzburg June eighth to eleventh 2011.
Design: This workshop brought together the communities of basic OA researchers, orthopedists and rheu-
matologists, imaging scientists, instrument manufacturers, and pharmaceutical representatives to focus on
three overlapping themes of joint anatomy, cartilage repair and clinical validation of imaging biomarkers.
Results: The workshop was held on the campus of the Paracelsus Medical University in Salzburg, Austria
from June 8e11, 2011; 133 attendees participated, representing 17 countries. The meeting was successful
in facilitating discussion, raising awareness and consolidating knowledge about application of imaging in
OA research studies and cartilage repair.
Conclusions: The OA research communities need to work alongside the regulatory, pharmaceutical, and
MRI industries to support the new ideas and engage in the positive reinforcement of resources to further
the new studies. A number of new initiatives were discussed to further break down obstacles to clinical
trial utility of imaging biomarkers.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Osteoarthritis (OA) imaging workshops
The general goal of the Workshops on Imaging in OA, which has
been endorsed by the Osteoarthritis Research Society International
(OARSI) and taken place thus far in Ainring/Salzburg (Germany/
Austria) in 2007, Boston (USA) in 2008, York (England) in 2009, and
Vancouver (Canada) in 2011, is to promote technical developments
and particularly applied research of in vivo imaging of OA, with
a particular focus on the relations with clinical outcomes. Each
workshop develops a (series of) theme(s) and delineates (1) what
imaging science has contributed thus far, (2) what the pressing
questions are and what imaging can help to address these andwhat
resources and research agenda are needed to move forward. In
addition to invited presentations and to podium discussions, the
meetings include oral and poster sessions from submitted abstracts,
one exclusively reserved for young investigators. Until this annual
series of workshops began, there was no dedicated forum for
interaction and collaborative development in this ﬁeld necessary to
bring together the critical mass for advancing this ﬁeld.to: Hunter, Rheumatology
Clinical School, University of
; Fax: 61-2-9906-1859.
Hunter).
s Research Society International. PTheseworkshops come at a critical time in OA research, at which
the mainstays of current OA management are analgesics and (total)
joint replacement. Efforts to develop therapies to slow, halt or
reverse the disease have been hampered by unresponsivemeasures
of the disease process. Unprecedented investment (both industry
and federally sponsored) is currently underway [i.e., the Osteoar-
thritis Initiative (OAI) and other large epidemiological studies]
aimed at addressing this pressing concern and developing or
qualifying new and responsive imaging markers. However, there is
little consensus on which structural imaging changes are related to
clinical outcomes (how a patient feels, functions or survives).
Imaging biomarkers may improve the assessment of the onset,
early development and progression of the disease, and could
greatly facilitate evaluation of treatment efﬁcacy in OA clinical
trials. Foremost among these is magnetic resonance imaging (MRI),
a non-invasive method for assessing joint morphology1,2.
The ﬁfth Annual Workshop
The goal of the ﬁfth Annual Workshop was to bring together all
stakeholders in the ﬁeld, to focus on three overlapping themes:
joint anatomy, cartilage repair and clinical validation of imaging
biomarkers. The workshop was held on the campus of the Para-
celsus Medical University (PMU) in Salzburg, Austria. From Juneublished by Elsevier Ltd. All rights reserved.
Table I
Presenters and titles of invited presentations at the ﬁfth Workshop on OA Imaging
Session 1:
Sample guiding question: what clinical outcomes should be used in cartilage repair
and which imaging biomarkers predict these most effectively?
Christoph Erggelet, Educatis University, Altdorf, Switzerland
Surgical cartilage repair techniques and their applicability to OA
Siegfried Trattnig, Center of Excellence for High Field MR, Medical University
of Vienna, Austria
Imaging techniques and biomarkers for monitoring cartilage repair
Stefan Marlovits, Medical University of Vienna, Austria
Clinical outcomes and their relationship with imaging biomarkers for
cartilage repair
Session 2:
Sample guiding question: what have we learned from the OAI and where do we go?
Michael Nevitt and John Lynch, OAI Cooridinating Center, University
of California, USA
Rates of structural OA progression (X-ray and MRI) in the OAI (and other
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countries: four from Australia, 15 from Austria, two from Belgium,
seven from Canada, four from Finland, one from France, 20 from
Germany, ﬁve from Japan, two from Mexico, nine from the
Netherlands, one fromNorway, one from Spain, three from Sweden,
12 from Switzerland, seven from the UK, and 38 from the US. Of the
133 participants, 56 represented 25 companies active in the ﬁeld.
The primary goals of the workshop were:
1. to promote discussion in the context of imaging biomarkers of
OA,
2. to revisit human joint anatomy and to relate state-of-the-art
imaging biomarkers to human joint anatomy,
3. to revisit imaging biomarkers of cartilage repair and present/
discuss recent data on the relationship of cartilage repair,
imaging biomarkers of cartilage repair, and clinical outcomes,
4. to present and discuss the most recent data on the relationship
of imaging biomarkers and clinical outcomes in OA.epidemiological studies)
Kent Kwoh, University of Pittsburgh, USA
Relating structural OA progression (X-ray and MRI) to clinical outcomes in the OAI
Gayle Lester, NIH, USA
Current status, future perspectives and funding opportunities for the OAI and OA
research
Session 3:
Sample guiding question: what clinical outcomes should be used in OA and which
imaging biomarkers predict these most effectively?
Gillian Hawker, Women’s College Hospital, University of Toronto, Canada
Clinical outcomes: what is the choice in OA?
Tuhina Neogi, Boston University, USA
Review of the relationship between X-ray biomarkers and clinical outcomes in OA
David Hunter, University of Sydney, Australia
Review of the relationship between MR imaging biomarkers and clinical outcomes
in OA
Gloria Matthews, Genzyme Corp., Cambridge, USA
What requirements does an imaging biomarker need to satisfy to be useful in
cartilage repair evaluation and DMOAD development?Pre-course in joint anatomy
This educational session was targeted at the full range of
participants including those relatively naive to anatomy to expe-
rienced investigators who apply this knowledge daily. Fifty-six
participants signed up and received small group, practical,
hands-on tutorials on all major human joints (knee, hip, shoulder
elbow, hand, foot) and the spine from anatomy tutors in the
dissection labs of PMU. Participants were given the opportunity to
study relevant structures such as the joint surfaces, ligaments and
special structures of diarthrodial joints as well as the speciﬁc
muscles involved in static and dynamic loading.
General program
The program generally consisted of invited key reviews on
selected topics by leaders in the ﬁeld (Table I), oral presentations
selected from abstracts (Table II), including four awards given to
young investigators (Fig. 2), and poster presentations selected from
abstracts (Table III) which had been submitted for the workshop.
Imaging biomarkers and clinical outcomes in cartilage repair
The ﬁrst review (Christoph Erggelet, University of Freiburg
Medical Center Freiburg/Germany) focused upon the principles of
surgical cartilage repair techniques and their applicability to OA,
including early prevention, treatment of symptoms and cartilage
changes, and replacement (arthroplasty). The presentationFig. 1. Participants of the ﬁfth imaging workshop insummarized repair techniques currently available and those being
actively investigated, including clinical trials intro their effective-
ness, and outlining current treatment options and their pros and
cons with particular reference to lesion size3.
Description of the imaging techniques and biomarkers for
monitoring cartilage repair was then reviewed by Siegfried Trattnig
(High Field MR Center, Medical University of Vienna, Austria). This
included methods for assessing (1) glycosaminoglycan content
[delayed gadolinium enhanced MRI of the cartilage (dGEMRIC),OA in the courtyard of PMU, Salzburg, Austria.
Table II
Presenters and titles of oral presentations at the ﬁfth Workshop on OA Imaging, selected from abstracts, including young investigator awards
Session 1: Cartilage Repair
Frank Roemer Augsburg & Boston Focal cartilage damage of the knee joint and risk for subsequent cartilage loss: an MRI-based analysis from the multi-center
OA study (MOST)
Katarina Kulmala Kuopio Contrast enhanced computed tomography in evaluation of spontaneous cartilage repair
Jasper Van Tiel Rotterdam CT arthrography to measure cartilage quality: inﬂuence of sulfated glycosaminoglycan content and structural composition of
extracellular matrix on contrast agent diffusion into cartilage
Jose Tamez Pena Monterrey A quantitative method for evaluating cartilage defect repair: intra- and inter- reader reproducibility
Shive Matt Montreal T2 MRI of repair cartilage reﬂects both tissue quality and quantity
Session 2: The OAI
Richard Frobell Lund MRI-based cartilage thickness loss and JSN in an OAI core progression sample, and their relationship with age, sex, and
body mass index (BMI)
Jose Tamez Pena Monterrey Spatio-temporal analysis of the signiﬁcant changes in cartilage morphology: data from the OAI
Wolfgang Wirth Salzburg Are short-term rates of MRI-based measures of knee cartilage loss markers of long-term change? 4-year data from the
OA initiative
Eveliina Lammentausta Oulu T2 reveals early cartilage changes during 2 years follow-up in subjects at risk for OA: data from the OAI
Robert Buck Minnesota Correlation of knee cartilage thickness change at 1 year and clinical outcome changes at 3 years: data from the OAI
Session 3: Young investigator awards
Claire Donoghue London Automatically generated novel diagnostic imaging biomarkers with data from the OAI
Karen Wiegant Utrecht Structural cartilage parameters on MRI and X-ray improve after treatment with knee joint distraction; a 2-year follow-up
Ida Haugen Oslo MRI is more sensitive than conventional radiography in detection of erosions in hand OA
Laura Laslett Hobart A 12-month randomized controlled trial of zoledronic acid for knee pain and subchondral BMLs
Session 4: Semi-quantitative imaging outcomes
Dieuwke Schiphof Rotterdam How risk factors associate to early OA shown with semi-quantitative measures on MRI in knees without signs of
radiographic OA
Jos Runhaar Rotterdam Malalignment and the presence of early signs of knee OA in obese women
Ali Guermazi Boston Does MRI depict progression of radiographically-deﬁned ‘end-stage OA (KL grade 4)’ longitudinally? The MOST study
Martin Englund, Lund and Boston Risk factors for medial meniscal lesions and (OR) extrusion on knee MRI in older US adults: MOST
Kent Kwoh, Pittsburgh Identiﬁcation of MRI morphologic features associated with different knee pain patterns
Session 5: Quantitative imaging outcomes
Michel Crema Boston dGEMRIC and its relationship with medial meniscal pathology: a 12-month follow-up study using 3.0 T MRI.
Toshiyuki Shiomi Osaka The inﬂuence of medial meniscectomy to the stress distribution of femoral cartilage in porcine knee e 3D reconstructed T2
mapping study
Satoru Tamura Osaka Assessment of knee cartilage in patients with Anterior cruciate ligament (ACL) rupture by 3D reconstructed T2 mapping
Greg Cicconetti Philadelphia Applying a statistical/graphical tool to characterize changes over time in MRI-based cartilage thickness measures
Robert Buck Minnesota Simulations to assess behavior of ordered values approach in clinical drug trials
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the collagen ﬁber network (global and zonal T2 mapping) and the
diffusion properties of cartilage (diffusion weighted imaging)4,
including in vivo human studies performed at 7 T. Examples of
application in different cartilage repair procedures were given and
the need for the clinical validation of the biochemical (composi-
tional) MR parameters was highlighted.
Clinical outcomes and their relationship with imaging
biomarkers for cartilage repair were reviewed by Stephan Marlo-
vits, Department of Orthopedics, Medical University of Vienna,
Austria. Not unlike OA, symptoms in cartilage repair do notFig. 2. Young investigator award winners of the ﬁfth imaging workshop in OA in the
lecture theater of PMU, Salzburg, Austria (from left to right: Laura Laslett, Hobart;
Karen Wiegant, Utrecht; Claire Donoghue, London; Ida Haugen, Oslo; Felix Eckstein)
(chairmen of young investigator award session and local organizer).necessarily correlate with structural cartilage damage and/or
structural improvement after repair. A key element is the applica-
tion of “morphological” imaging, to allow for semi-quantitative
scoring (e.g., the Magnetic Resonance Observation of Cartilage
Repair Tissue (MOCART) score5), in order to assess the structural
status of the repair. Additional applications in clinical studies
include biochemical imaging and biomechanical MRI (howdoes the
tissue function under movement and mechanical loading)6.
The OAI
The OAI is currently and will continue to provide an unparalleled,
state-of-the-art longitudinal public database of images and clinical
outcome information to facilitate the discovery of biomarkers for
development and progression of OA7. The workshop brought
together experts in the ﬁeld that helps to shape what questions
might be prioritized to best utilize this vast imaging resource.
The ﬁrst presentation by Michael Nevitt and John Lynch (Coor-
dinating Center of the OAI, University of California, San Francisco),
focused on new radiologic outcomes data from entral image
assessments, including semi-quantitative and quantitative readings
of ﬁxed ﬂexion knee radiographs, methods and results for deter-
mining progression, tips on using the data, and comparisons with
MRI-measured cartilage thickness change. Rates of progression in
OAI appear to be comparable to other observational studies [i.e., the
summary measures from the OARSI Food and Drug Administration
(FDA) initiative]8. MRI appears to pick up higher number of
progressors than radiography, and as radiographic OA becomes
more severe [e.g., greater KellgreneLawrence (KL) or joint space
narrowing (JSN) grades], MRI may become more responsive
than radiographic measurement of joint space width (JSW).
Table III
Presenters and titles of poster presentations at the ﬁfth Workshop on OA imaging
Lickorish D North Grafton Quantiﬁcation of trabecular bone vascularity in a rabbit model of OA by perfusion micro-computed tomography
Maschek S. Munich Does ankle cartilage adapt to strong alterations in loading environment after transplantation to the knee
(Van Nees rotationplasty)?
King. A.J. Calgary 3D visualization and measurement of the posterior cruciate ligament in a ﬂexed knee using open-bore 0.2 T MRI
Dam E.B. Copenhagen Automatic segmentation of bone and cartilage from knee MRI
Lammentausta E. Oulu In vivo transport of GD-DTPA2 e into human knee cartilage
Eckstein F. Salzburg Cartilage thickness, denuded areas, and bone size in knees prior to TKR e data from the OAI
Sitoci H. Munich Nocturnal changes in femoro-tibial cartilage thickness in young healthy adults
Roemer F.W. Augsburg Longitudinal within-grade scoring of cartilage and BMLs: validity analyses from the MOST study
Cicconetti G. Philadelphia A statistical/graphical tool to identify knee OA phenotypes based on MRI cartilage thickness measures
Haugen I.K. Oslo The role of MRI-deﬁned synovitis in hand OA
Wyman B.T. Groton Compression of the knee upon weight loading in healthy and OA subjects as measured by MRI and X-ray
Saunders F.R. Aberdeen Active shape modeling of bilateral knee OA in the OAI
Driban J.B. Boston Hip bone mineral density does not inﬂuence tibio-femoral BML size
Marques J. Copenhagen Quantiﬁcation of trabecular tibia bone structure related to the presence of OA
Marques J. Copenhagen Prediction of cartilage loss by analysis of trabecular tibia bone structure
Riek J.K. New York A multi-center comparison of T2 relaxation times calculated centrally vs those generated directly by the MR scanner
Beattie K.A. Hamilton Longitudinal changes in intermuscular fat volume and quadriceps muscle volume in the thighs of female OAI participants
Rudolphi K. Frankfurt Improved assessment by quantitative digital histomorphome-try of histopathological changes of articular cartilage in a
surgical model of post-traumatic OA of the knee joint in rats
Stok K.S. Zürich Comprehensive morphological characterization of arthritis in animal models by micro-computed tomography
Stok. K.S. Zürich An intergrative imaging approach for examining bone and cartilage tissues in the osteoarthritic joint e a pilot study
Siorpaes K. Salzburg Interobserver variation of quantitative meniscus analysis using coronal MPR DESSWE and IW TSE MR imaging
Blöcker K. Salzburg Size and position of the healthy meniscus, and its correlation with sex, height, weight, bone size, and age
Kinds M.B. Utrecht Are separate quantitative radiographic features (Knee Images Digital Analysis (KIDA)) of knee OA very early in the disease
(check) associated with clinical progression during 4-year follow-up?
Kinds M.B. Utrecht Feasibility of bone density evaluation using plain digital radiography
Hudelmaier M. Salzburg 1-year rate of change in subchondral bone size in osteoarthritic and healthy knees
Sattler M. Salzburg Side differences of thigh muscle cross sectional areas in knees with the same radiographic OA (KL) grade, but unilateral
frequent pain
Cromer M. Sydney Quantitative analysis in the medial tibio-femoral compartment over 1 year
Nishii T. Osaka Signiﬁcant inﬂuence on load response of knee cartilage T2 by meniscus disorder e a loading MRI study
Noelle-Klocke N.F., Iowa City Toward T1RHO in the clinic: a 3.0 T and 1.5 T comparison
Stannus O.P. Hobart Cartilage signal intensity on MRI: association with BMI, cartilage defects and type II collagen break down
Buck R.J. Minneapolis Classiﬁcation and distribution of cartilage thickness change in subject knees: data from the OAI
Tummala S. Copenhagen Diagnosis of OA by automatic quantiﬁcation of incongruity from knee MRI
Tamura S. Osaka 3D patterns of acetabular cartilage damage in hip dysplasia at pre- and early arthritic stages; a high-resolutional CT
arthrography study
Lowitz T. Nürnberg Quantitative CT for knee OA
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tion of quantitative JSW change and its intersubject variability, with
change in tibial rim distance serving as a surrogate for change in
alignment of the tibial plateau relative to the X-ray beam. Adjusting
for this effect may improve JSW as an outcome; however there
appears to be additional need to develop methods for dealing with
non-ideal radiographs for JSW measurement changes.
Kent Kwoh (University of Pittsburgh) summarized emerging
data on the relationship of bone marrow lesions (BMLs), effusion,
synovitis, and denuded bone areas (dABs) with pain in the OAI, as
a function of score/size and location. New opportunities have
emerged within the OAI to relate these and other morphological
features to total knee replacement (TKR). Thus far (from baseline
through to the 72-month follow-up visit) 254 TKRs have reported
in the OAI,18 with a baseline KL grade of 0 or 1, 54 with 2, 98 with 3,
and 84 with a KL grade of 4. New data is emerging indicating that
MRI cartilage morphometry [denuded bone areas (dAB) and carti-
lage thickness] as well as a range of clinical variables (pain and
function) predicts the advent of TKR.
Finally, Gayle Lester [National Institute of Health (NIH)] summa-
rized the current status, future perspectives and funding opportu-
nities for the OAI9. She pointed out that the OAI is now funded for
a total of 8 years of follow-up, with the 60-month visits almost
completed, the 72-month visits approximately 70% completed, and
the 84-month visit started in February 2011. Retention remains high
with follow-up in the study of about 80% of the original cohort. The
OAI contract ends in 2014/2015, and the goal is to transition to grants
for follow-up analyses. She encouraged more studies using OAI andancillary studies, potentially introducing novel imaging methods
within the last 2 years of the study.
Relationships of imaging biomarkers with clinical outcomes
OA is extraordinarily complex with marked heterogeneity in
onset, clinical presentation, rate of disease progression, pattern of
joint involvement and different tissue structures being affected. An
important challenge is that the current approval of potential
disease modifying OA drugs (DMOADs) requires structural alter-
ation to be linked to a clinical beneﬁt, either at the same time of
structural measurement or later. With this in mind it is important
that improvements in OA structural features are related to symp-
toms, function, or joint survival, i.e., time to (need for) TKR.
As presented by Gillian Hawker (University of Toronto, Canada),
the current clinical focus is onpain, as this is the predominant reason
a patient will seek clinical care. However, there are many down-
stream effects of pain, including fatigue, depressed mood and
disability, which amplify pain and its experience over time. These
should not be forgotten in the assessment of OA, with a need for
a broader bio-psycho-social perspective10. Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) pain scores
appear to largely reﬂect pain occurring with activity, and the corre-
lation with function subscales is high: therefore WOMAC scores are
apparently insufﬁcient, if one is interested in pain and disability as
separate constructs. The OARSIeOutcome Measures in Rheumatoid
Arthritis Clinical Trials (OMERACT) working group identiﬁed distinct
types of OA pain, one being a dull, aching pain, which became more
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generally more intense, often unpredictable, and emotionally
draining. Intermittent, intense, unpredictable pain has the greatest
impact on quality of life. New subscales are being developed that
account for differences in types of pain and that are independent of
joint function. An OMERACTeOARSI working group found that
patients with an indication to TKR had greater pain and disability
than thosewithout, but due to considerable overlap in the scores the
groupwas unable to determine relevant cut-points, so that a concept
of virtual TKR is still under development11.
As outlined by Gloria Matthews (Genzyme Corporation, Cam-
bridge, MA), the guidance and current gold standard for measuring
clinical efﬁcacy of DMOADs is radiographic JSN or change in JSW12,
from which the integrity and thickness of articular cartilage (and
the meniscus) are inferred13,14. The current guidance describes
a process of drug approval for speciﬁc indications in OA, e.g.,
treatment of symptoms, delays in structural progression, and even
prevention. JSN is currently recommended as an imaging endpoint
for clinical trials on DMOADs by both the FDA and the European
Agency for the Evaluation of Medicinal Products (EMEA) and ideally
should be paralleled by symptom evidence. Alternatively, plans for
assessing long-term clinical outcomes should be discussed with the
agencies. At present, alterations in structural progression need to
be determined by radiography, but MRI is now also recommended
for clinical trials by the agencies for cartilage morphology (volume/
thickness) assessment. It is possible that newer technologies may
be approved in the future, including biochemical markers, MRI or
even ultrasound, once appropriately validated15,16. However,
minimum clinically important differences need to be established
and the durability of the effect demonstrated. The FDA guidance is
currently under review with efforts from an OARSI led initiative17.
With regard to the evaluation of cartilage repair procedures, MRI
may serve as a co-primary or secondary endpoint, with pain and
function being primary endpoints. The MRI techniques applied
need to be clearly deﬁned in the study protocol and images should
be evaluated by at least two independent (blinded) readers. The
protocol should include prospectively stated descriptions of the
image review process, including a plan for resolving conﬂicting
readings. In contrast to the FDA, the EMA recommends second look
arthroscopy, ranking histological evaluation higher than MRI.
As outlined by Tuhina Neogi (Boston University, Boston, MA),
X-ray changes of OA typically take a long time; incidence rates of
knee OA are about 6% over 30e36 months. Difﬁculties in studying
relevant clinical OA outcomes in epidemiologic studies arise from
the fact that all clinical outcomes are inﬂuenced by factors other
than OA itself. Further, pain is subjective, function is a person-level
concept, whereas OA is a joint-level phenomenon, and TKR
depends upon factors other than disease, pain or function. There-
fore, at present, KL grade or JSW cannot accurately predict TKRwith
appropriate speciﬁcity, neither when analyzed cross-sectionally
nor longitudinally. Although the relationship between radio-
graphic change and clinical outcomes is often described as weak,
this is potentially due to between-person confounding. Novel
analytic techniques (between-knee, within-person comparisons)
are ﬁnding stronger associations18 and these are consistent across
different racial/ethnic groups. These studies show that JSN is more
strongly associated with pain than osteophyte scores. Ideally, pain
should be assessed more frequently than is currently feasible in
most observational studies, to more accurately capture pain ﬂuc-
tuations. It is stressed that alterations in some structural lesions
may result in short-term clinical outcome effects, but for others,
any potential effect may be detected only with longer follow-up.
David Hunter (University of Sydney, Sydney Australia) reviewed
the relationship between MRI biomarkers and clinical outcomes in
OA. MRI measures [especially synovitis, effusion, BMLs, denudedareas of bone (dABs)] provide a stronger relation to symptoms than
other structural changes19. There are a number of complex hurdles
with regards validating and qualifying MRI biomarkers that need to
be overcome, to utilize these measures in clinical trials and gain
regulatory assent as an approved endpoint.
Round table discussion and new directions
The conference closed with a vigorous discussion on “How can
we clinically validate and qualify existing imaging biomarkers for
cartilage repair and OA?” As part of this discussion a number of new
initiatives and propositions were discussed that could help to
overcome some of the obstacles in the ﬁeld.
One proposal was to not view structural (radiographic) OA as
a disease, as long as it represents an asymptomatic condition.
However, structural OA may be considered a “risk factor” of the
disease (i.e., symptomatic OA). A DMOAD thus should not be neces-
sarily expected to have an immediate or short-term effect on clinical
outcomes (i.e., symptoms and function), but may reduce the risk of
disease onset or disease progression over longer periods. In that
sense, DMOAD treatment may be equivalent to treatment of high
blood pressure, high lipid or high glucose serum levels in context of
stroke, coronary heart disease, or diabetes. Prospective, observational
studies are needed showing to what extent structural imaging
biomarkers can predict clinical outcomes years later. However, some
of the most promising novel imaging biomarkers alsowill have to be
tested in parallel with radiography in initial therapeutic (DMOAD)
trials, in order to demonstrate their usefulness to regulatory agencies.
The STAIRe Stroke Treatment Academic Industry Round table e
Consensus Conferences potentially provide a useful model for the
OA ﬁeld20. These are intended to improve the understanding of
issues critical to stroke drug and device development and advance
knowledge essential to the successful development of new acute
stroke treatments. STAIR assembles a select group of leading
scientists from industry, academia and government (including FDA)
to initiate a consensus process that results in the development of
recommendations, and from which a manuscript is submitted to
a leading medical journal.
Foundation for National Institutes of Health (fNIH) OA
biomarkers consortium
It is evident that new investigational paradigms in drug devel-
opment must be advanced to facilitate both discovery and clinical
development, without sacriﬁcing basic regulatory standards of
safety and efﬁcacy21. Cognizant of these challenges, there is
evidence that the stakeholders in the pharmaceutical enterprise
recognize the need for a shift in the approach to drug
development22,23.
The Biomarkers Consortium is a publiceprivate partnership
managed by the FNIH (http://www.FNIH.org) with broad participa-
tion from many private, academic, and non-proﬁt stakeholders. It
endeavors to identify, develop, and qualify biological markers
(biomarkers) to support new drug development, preventive medi-
cine, andmedical diagnostics21,24. An OA Biomarkers Consortium has
recently formed under the organizational umbrella of the fNIH25. The
hope is that through this mechanism an approach to clinical valida-
tion and qualiﬁcation of high potential OA biomarkers will be facili-
tated providing the most effective means to driving breakthroughs
leading to viable new chemical entities for patients with OA.
Next meeting
The next workshop will be a joint workshop (sixth OA imaging
workshop in combination with the OARSI OA Biomarker Workshop
D.J. Hunter, F. Eckstein / Osteoarthritis and Cartilage 19 (2011) 1263e12691268III) and will take place at Hilton Head (South Carolina) from July
12th to 14th 2012. The highlights and focus of the meeting will be:
1. A pre-course on the practical use of imaging biomarkers in
clinical studies/ trials.
2. Discussion of the pathway for validation and qualiﬁcation of OA
biomarkers.
3. Discussion of the level of validation/ qualiﬁcation key efﬁcacy
of intervention biomarkers.
4. Discussion of the steps needed to overcome obstacles and
improve biomarker qualiﬁcation.
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